What insurance policy changes affect HCPCS J7174?

There are 11 tracked policy changes affecting HCPCS J7174, including updates from Humana, Anthem BCBS, Florida Blue. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J7174?

Payers that have issued tracked updates for HCPCS J7174 include: Humana, Anthem BCBS, Florida Blue, Blue Cross Blue Shield of Rhode Island, Kansas Medicaid (KanCare), Michigan Medicaid - MDHHS, Molina Healthcare.

How do I get notified when HCPCS J7174 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J7174. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J7174?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J7174 Insurance Policy Changes

HCPCS J7174 is officially defined as "Injection, fitusiran, 0.04 mg." HCPCS J7174 is referenced in 11 tracked payer policy changes from Humana, Anthem BCBS, and 5 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J7174 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
Kymriah™ (tisagenlecleucel) (Revised)
Humana·Effective Aug 26, 2026
Humana Kentucky Medicaid has revised its Kymriah (tisagenlecleucel) prior authorization policy effective August 26, 2026. The policy maintains three distinct approval pathways for large B-cell lymphoma (DLBCL and follicular lymphoma) in adults ≥18 years, and B-cell precursor acute lymphoblastic leukemia (ALL) in patients up to 25 years. All approvals require prior authorization, are limited to one lifetime dose, and require lymphodepleting chemotherapy unless contraindicated. Key exclusions include prior gene therapy, prior anti-CD19/anti-CD3 therapies, active hepatitis B/C, HIV/AIDS, and (for lymphoma cases) prior allogeneic transplant or CNS lymphoma.
High impact
[Virginia] Specialty pharmacy updates for May 2026
Anthem BCBS·Effective Aug 1, 2026
Effective August 1, 2026, Anthem Virginia is implementing prior authorization, quantity limits, step therapy, and site of care requirements for 13 specialty pharmacy medications. Billing teams must update systems to require prior authorization for these drugs before dispensing and verify medical necessity documentation. Patients currently receiving these medications without prior auth will need authorization for continued coverage.
High impact
[Georgia] Specialty pharmacy updates for May 2026
Anthem BCBS·Effective Aug 1, 2026
Effective August 1, 2026, Anthem Georgia is implementing new prior authorization, quantity limit, step therapy, and site of care requirements for 17 specialty pharmacy medications. Billing teams must update systems to require prior authorization for these drugs before the effective date, as patients currently receiving these medications without authorization will now require approval for continued use.
High impact
Medicare Part B Step Therapy May Updates
Florida Blue·Effective May 15, 2026
Florida Blue Medicare updated its Part B Step Therapy program effective May 15, 2026, adding new non-preferred drugs and changing preferred status for medications in Asthma, Cancer, and Hemophilia categories. Providers must try preferred alternatives before prescribing non-preferred drugs or face coverage denials.
High impact
Additional HCPCS Level II Code Changes and Modifier Changes
Blue Cross Blue Shield of Rhode Island·Effective Oct 1, 2025
Blue Cross Blue Shield of Rhode Island updated HCPCS Level II codes and modifiers effective October 1, 2025, affecting coverage and reimbursement rules for various procedures. Multiple codes now have different coverage policies for Professional vs Institutional providers, and some require specific modifiers or medical review.
Medium impact
[New York] Specialty pharmacy updates for May 2026
Anthem BCBS·Effective Aug 1, 2026
Effective August 1, 2026, Anthem Blue Cross specialty pharmacy policies are changing for New York commercial plans. Seven specialty drugs now require prior authorization, quantity limits, step therapy reviews, or site of care determinations. Billing teams must implement these requirements in their systems to avoid claim denials for patients currently receiving these medications without prior auth.
Medium impact
[Ohio] Specialty pharmacy updates for May 2026
Anthem BCBS·Effective Aug 1, 2026
Effective August 1, 2026, Anthem is implementing new prior authorization, quantity limit, step therapy, and site of care requirements for 16 specialty pharmacy medications across multiple clinical criteria documents. Billing teams must update systems to require prior authorization for these drugs and verify step therapy status (non-preferred medications require step therapy) before claims submission. Patients currently receiving these medications without authorization may be affected, requiring proactive outreach.
Medium impact
Factor VIII Replacement Products (Hemophilia A) (Revised)
Humana·Effective Dec 17, 2025
This is a revised Factor VIII replacement product prior authorization policy for Hemophilia A treatment, effective January 20, 2017, with most recent updates on December 17, 2025. The policy covers 18 Factor VIII products across two main indications: routine bleeding prophylaxis and on-demand bleeding control/perioperative management. All Factor VIII product requests now require prior authorization approval with specific clinical criteria documentation for Medicaid/Medicare Kentucky members.
Medium impact
KMAP BULLETIN: HCPCS Codes Updates – October 2025
Kansas Medicaid (KanCare)·Effective Oct 1, 2025
Kansas Medicaid (KMAP) is adding 30 new HCPCS codes for coverage and discontinuing 7 existing codes effective October 1, 2025. This affects billing for medical devices, injectable drugs, and other supplies covered under Kansas Medicaid programs.
Medium impact
MMP 25-46: Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) Code Updates
Michigan Medicaid - MDHHS·Effective Oct 1, 2025
Michigan Medicaid has updated CPT and HCPCS code coverage effective October 1, 2025, adding new covered codes for various provider types and discontinuing several codes as of September 30, 2025. The policy also provides retroactive coverage for some existing codes dating back to June 2025.
Medium impact
Prior Authorization Requests Effective 10/1/25
Molina Healthcare·Effective Oct 1, 2025
Molina Healthcare of New York is implementing new prior authorization requirements for transplant/gene therapy drugs and skin substitutes effective October 1, 2025, while removing prior auth requirements for certain ASC procedures (33904) unless performed out-of-network.

All billing codes J3590 99213 99214 99212 99202 99203

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Kymriah™ (tisagenlecleucel) (Revised)

[Virginia] Specialty pharmacy updates for May 2026

[Georgia] Specialty pharmacy updates for May 2026

Medicare Part B Step Therapy May Updates

Additional HCPCS Level II Code Changes and Modifier Changes

[New York] Specialty pharmacy updates for May 2026

[Ohio] Specialty pharmacy updates for May 2026

Factor VIII Replacement Products (Hemophilia A) (Revised)

KMAP BULLETIN: HCPCS Codes Updates – October 2025

MMP 25-46: Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) Code Updates

Prior Authorization Requests Effective 10/1/25